SCHEMBL3339751

SCHEMBL3339751

CC(C)c1cncc(O[C@H]2CC[C@@H](C(=O)Nc3ccc(OC(F)F)cc3)CC2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 4/20 0.47
POLB P06746 3/20 0.43
ROCK2 O75116 3/20 0.39
ROCK1 Q13464 3/20 0.39
ACACB O00763 1/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
RPS6KA5 O75582 2/20 0.38
PKN2 Q16513 2/20 0.38
LRRK2 Q5S007 2/20 0.38
CHUK O15111 1/20 0.38
PRKD3 O94806 1/20 0.38
CDK1 P06493 1/20 0.38
CDK2 P24941 1/20 0.38
LTK P29376 1/20 0.38
CDK8 P49336 1/20 0.38
PRKX P51817 1/20 0.38
CDK5 Q00535 1/20 0.38
PRKCQ Q04759 1/20 0.38
PRKCD Q05655 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3332840 0.79 ABL1 (0.47) ABL1POLBNPSR1NAMPT
SCHEMBL3327606 0.78 ABL1 (0.45) ABL1POLBACACBGSK3AGSK3B
SCHEMBL10143875 0.76 POLB (0.52) ABL1POLBHTT
SCHEMBL3333489 0.73 KDR (0.49) ABL1POLBGSK3AGSK3BHTT
SCHEMBL3332482 0.73 POLB (0.59) ABL1POLBACACBNAMPT
SCHEMBL3347350 0.72 HCRTR2 (0.52) ABL1POLBGSK3AGSK3BTP53
SCHEMBL3344765 0.70 POLB (0.46) ABL1POLBACACBHTT
SCHEMBL12058718 0.69 POLB (0.60) ABL1POLBGSK3B
SCHEMBL3367149 0.66 ABL1 (0.50) ABL1POLBGSK3AGSK3B
SCHEMBL10192288 0.66 EPHX2 (0.46) ABL1POLBHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653125-B2 Cyclohexane derivative having NPY Y5 receptor antagonism SHIONOGI CO., LTD. (JP) 2014-02-18 US disclosed
US-20120004227-A1 CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM SHIONOGI & CO., LTD. (JP) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004227-A1 CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM NPY5R, NPY1R, NPY2R ABL1 1113/4885POLB 4701/4885ROCK2 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.